Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01730729 · ClinicalTrials.gov registry record · Early Phase 1
Cabergoline in Metastatic Breast Cancer
A Early Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT01730729 is a Early Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 20 participants.
The verdict
NCT01730729, a Early Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Prolactin is a hormone produced in the pituitary gland. Previous studies have revealed that elevated levels of the hormone prolactin might be associated with an increased risk of breast cancer. Cabergoline has been shown to lower prolactin levels in the blood. The purpose of this study is to evaluate the effectiveness of cabergoline in treating metastatic breast cancer disease in those who test positive for the prolactin receptor.
Interventions
- DRUG cabergoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-02-11 |
| Est. Completion | 2017-10-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01730729
The ClinicalTrials.gov registry entry for NCT01730729 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cabergoline is the first listed.
NCT01730729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01730729 about?
NCT01730729 is a clinical study titled "Cabergoline in Metastatic Breast Cancer". Prolactin is a hormone produced in the pituitary gland. Previous studies have revealed that elevated levels of the hormone prolactin might be associated with an increased risk of breast cancer. Cabergoline has been shown to lower prolactin levels in the blood. The purpose of this study is to evalua...
What is the current status of trial NCT01730729?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2013-02-11. Estimated completion is 2017-10-27.
What interventions are being tested in trial NCT01730729?
The interventions under investigation include: cabergoline (DRUG).
Who is sponsoring clinical trial NCT01730729?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.